1. Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Acromegaly - Part 1: Diagnostic and Clinical Issues
- Author
-
Roberto Attanasio, Alessandro Bozzao, Laura De Marinis, Michele Zini, Maria Rosaria Ambrosio, Giovanni Lasio, Maurizio Poggi, Laurence Katznelson, Edoardo Guastamacchia, Vincenzo Toscano, Francesco Logoluso, Renato Cozzi, Pietro Maffei, Ernesto De Menis, Andrea Lania, and Philippe Chanson
- Subjects
Position statement ,Pediatrics ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,030209 endocrinology & metabolism ,Disease ,Article ,NO ,Comorbidities ,03 medical and health sciences ,0302 clinical medicine ,Acromegaly ,medicine ,Humans ,Immunology and Allergy ,Insulin-Like Growth Factor I ,LS4_3 ,Societies, Medical ,Transsphenoidal surgery ,Discrepant ,Human Growth Hormone ,business.industry ,GH ,IGF-I ,Pituitary ,Sleep apnea ,medicine.disease ,Clinical Practice ,Endocrinologists ,Italy ,Practice Guidelines as Topic ,Pegvisomant ,business ,030217 neurology & neurosurgery ,medicine.drug ,Rare disease - Abstract
Acromegaly is a rare disease. Improvements in lifespan in these patients have recently been reported due to transsphenoidal surgery (TSS), advances in medical therapy, and strict criteria for defining disease remission. This document reports the opinions of a group of Italian experts who have gathered together their prolonged clinical experience in the diagnostic and therapeutic challenges of acromegaly patients. Both GH and IGF-I (only IGF-I in those treated with Pegvisomant) are needed in the diagnosis and follow-up. Comorbidities (cardio-cerebrovascular disease, sleep apnea, metabolic derangement, neoplasms, and bone/joint disease) should be specifically addressed. Any newly diagnosed patient should be referred to a multidisciplinary team experienced in the treatment of pituitary adenomas.
- Published
- 2020